Arcturus Therapeutics
ARCTArcturus Therapeutics is a clinical-stage biotechnology company specializing in messenger RNA (mRNA) medicines for rare diseases and infectious pathogens.
Table of contents
Earnings
Next report
Aug 10, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Arcturus Therapeutics is a clinical-stage biotechnology company specializing in messenger RNA (mRNA) medicines for rare diseases and infectious pathogens. The company leverages proprietary self-amplifying mRNA (sa-mRNA) and lipid nanoparticle (LNP) delivery technologies to develop a pipeline of therapeutics and vaccines. Its core value proposition lies in its ability to enable prolonged protein expression at lower doses compared to conventional mRNA platforms.
A pioneer in self-amplifying mRNA technology, holding the first global regulatory approval for an sa-mRNA vaccine. The company maintains a strong intellectual property position with over 500 patents and pending applications.
Questions, answered.
- What is Arcturus Therapeutics's market cap?
- Arcturus Therapeutics (ARCT) has a market capitalization of $163.7M and trades on NASDAQ.
- Who are Arcturus Therapeutics's competitors?
- Arcturus Therapeutics's key competitors include Moderna, Pfizer, Vertex Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Arcturus Therapeutics partner with?
- Arcturus Therapeutics's notable partners include CSL Seqirus, Meiji Seika Pharma, Cystic Fibrosis Foundation, and others.
- What subsidiaries does Arcturus Therapeutics have?
- Arcturus Therapeutics's subsidiaries include ARCALIS, Inc., Arcturus Therapeutics Ltd..
- Where is Arcturus Therapeutics headquartered?
- Arcturus Therapeutics is headquartered in United States of America and employs approximately 180 people. It has been publicly traded since 2013.